Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Table 3 Association of clinical, pathological and genomic characteristics with PFS and OS in the control group

Characteristics		N (107)	Progression Free Survival			Overall Survival
			HR	95% CI	P	HR	95% CI	p
Sex	Females	39	1			1
	Males	68	0.97	0.65-1.45	0.893	0.83	0.51-1.30	0.397
Age	≤ 65 years	60	1			1
	>65 years	47	0.78	0.51-1.15	0.197	0.94	0.61-1.44	0.782
ECOG PS	0	83	1			1
	1-2	24	1.34	0.84-2.31	0.196	2.32	1.68-6.23	0.0004
Previous adjuvant CT	No	75	1			1
	Yes	32	1.13	0.74-1.75	0.562	0.77	0.49-1.22	0.268
No. of metastatic sites	1	57	1			1
	>1	50	1.10	0.75-1.62	0.632	0.88	0.57-1.34	0.542
Liver-only metastases	No	68	1			1
	Yes	39	0.81	0.54-1.19	0.270	0.97	0.63-1.51	0.901
High CEA level	No	85	1			1
	Yes	22	1.45	0.91-2.68	0.109	1.91	1.22-4.36	0.010
-1498	C/C	25	1			1
	C/T	55	1.09	0.68-1.76	0.719	0.89	0.50-1.55	0.662
	T/T	27	0.89	0.50-1.54	0.653	0.73	0.36-1.39	0.311

ISSN: 1471-2407